Origins and Ownership of Remdesivir: Implications for Pricing

Request for emergency use authorization for use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients, US Food and Drug Administration, available at <https://www.fda.gov/media/137564/download> (last visited May 1, 2020).

M. Wang , R. Cao , L. Zhang , X. Yang , et al., “Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in vitro,” Cell Research 30, no. 3 (2020): 269-271.

J.H. Beigel , K.M. Tomashek , L.E. Dodd , et al., “Remdesivir for the Treatment of Covid-19 - Preliminary Report,” New England Journal of Medicine (2020) (E-pub ahead of print).

HHS announces shipments of donated remdesivir for hospitalized patients with COVID-19, U.S. Department of Health & Human Services, available at <https://www.hhs.gov/about/news/2020/05/09/hhs-ships-first-doses-of-donated-remdesivir-for-hospitalized-patients-with-covid-19.html> (last visited May 25, 2020).

A. Hill , J. Wang , J. Levi , K. Heath , and J. Fortunak , “Minimum Costs to Manufacture New Treatments for COVID-19,” Journal of Virus Eradication 6, no. 2 (2020): 61-69.

Alternative Pricing Models for Remdesivir and Other Potential Treatments for COVID-19, Institute for Clinical and Economic Review (ICER), available at <https://icer-review.org/wp-content/uploads/2020/05/ICER-COVID_Initial_Abstract_05012020-3.pdf> (last visited May 25, 2020).

ICER Provides First Update to Pricing Models for Remdesivir as a Treatment for COVID-19, Institute for Clinical and Economic Review (ICER), available at < https://icer-review.org/announcements/updated_icer-covid_models_june_24/> (last visited June 30, 2020).

“Remdesivir, the First Coronavirus Drug, Gets a Price Tag,” The New York Times, available at <https://www.nytimes.com/2020/06/29/health/coronavirus-remdesivir-gilead.html> (last visited June 30, 2020).

D. Siegel , H.C. Hui , E. Doerffler , M.O. Clarke , et al., “Discovery and Synthesis of a Phosphorami-date Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses,” Journal of Medicinal Chemistry 60, no. 5 (2017): 1648-1661.

Siegel, supra note 9.

Siegel, supra note 9; T.K. Warren , R. Jordan , M.K. Lo , et al., “Therapeutic Efficacy of the Small Molecule GS-5734 Against Ebola Virus in Rhesus Monkeys,” Nature 531, no. 7594 (2016): 381–385. (published correction appears in ACS Chemical Biology 11, no. 5 (2016):1463).

Siegel, supra note 9.

S. Koplon , “Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus,” UAB News, available at <https://www.uab.edu/news/health/item/11082-investigational-compound-remdesivir-developed-by-uab-and-nih-researchers-being-used-for-treatment-of-novel-coronavirus> (last visited April 11, 2020).

M.L. Agostini , E.L. Andres , A.C. Sims , et al., “Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease,” mBio 9, no. 2 (2018): e00221-18.

T.P. Sheahan , A.C. Sims , S.R. Leist , et al., “Comparative Therapeutic Efficacy of remdesivir and Combination lopinavir, ritonavir, and interferon beta against MERS-CoV,” Nature Communications 11, no. 1 (2020): 222.

Role of the Federal Government in the Development of Remdesivir, Knowledge Ecology International, available at <https://www.keionline.org/wp-content/uploads/KEI-Briefing-Note-2020_1GS-5734-Remdesivir.pdf> (last visited March 23, 2020).

GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen, ClinicalTrials.gov, available at <https://clinicaltrials.gov/ct2/show/NCT02818582> (last visited June 3, 2020).

S. Mulangu , L.E. Dodd , R.T. Davey , O.T. Mbaya , et al., “A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics,” New England Journal Medicine 381, no. 24 (2019): 2293-2303.

A. Joseph , “As the Coronavirus Spreads, a Drug that Once Raised the World’s Hopes is Given a Second Shot,” Stat News, available at <https://www.statnews.com/2020/03/16/remdesivir-surges-ahead-against-coronavirus/?utm_content=buffer8f626&utm_medium=social&utm_source=twitter&utm_campaign=twitter_organic.> (last visited April 11, 2020).

J. Cohen , “Chinese Researchers Reveal Draft Genome of Virus Implicated in Wuhan Pneumonia Outbreak,” American Association for the Advancement of Science, available at <https://www.sciencemag.org/news/2020/01/chinese-researchers-reveal-draft-genome-virus-implicated-wuhan-pneumonia-outbreak> (last visited June 3, 2020).

W.F. Zhang , P. Stephen , J.F. Thériault , R. Wang , S.X. Lin , “Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks,” Journal of Physical Chemistry Letters 11 (2020):4430-4435.

Wang et al., supra note 2.

C.J. Gordon , E.P. Tchesnokov , J.Y. Feng , D.P. Porter , and M. Gotte , “The Antiviral Compound Remdesivir Potently Inhibits RNA-Dependent RNA Polymerase from Middle East Respiratory Syndrome Coronavirus,” Journal of Biological Chemistry 295, no. 15 (2020): 4773-4779.

de Wit, supra note 23.

Y. Wang , D. Zhang , G. Du , et al., “Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial,” Lancet 395, no. 10236 (2020):1569-1578. (Published correction appears in Lancet, 395, no. 10238 (2020):1694).

J. Grein , N. Ohmagari , D. Shin , et al., “Compassionate Use of Remdesivir for Patients with Severe Covid-19,” New England Journal of Medicine (2020) (E-pub ahead of print).

Beigel, supra note 3.

Supra note 16.

Search Orphan Drug Designations and Approvals, U.S. Food and Drug Administration (FDA), available at <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=490515> (last visited April 11, 2020).

L. Fang and S. Lerner , “Coronavirus Treatment Developed by Gilead Sciences Granted ‘Rare Disease’ Status, Potentially Limiting Affordability,” The Intercept, available at <https://theintercept.com/2020/03/23/gilead-sciences-coronavirus-treatment-orphan-drug-status/> (last visited April 11, 2020).

FDA gives Gilead a seven year regulatory monopoly for remdesivir to treat COVID-19, on grounds it is an “Orphan” treating a rare disease, Knowledge Ecology International, available at <https://www.keionline.org/32546> (last visited March 23, 2020).

D. Hemel and L.L. Ouellette , “Pharmaceutical Profits and Public Health Are Not Incompatible,” New York Times, available at <https://www.nytimes.com/2020/04/08/opinion/coronavirus-drug-company-profits.html> (last visited April 11, 2020).

Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation, Gilead Company Statements, available at <https://www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-request-to-rescind-remdesivir-orphan-drug-designation> (last visited April 11, 2020).

Sheahan 2017, supra note 14; Supra note 14; Sheahan 2020, supra note 15.

Supra note 16.

Supra note 16..